Drug results: 1

rilzabrutinib Rilzabrutinib is a selective, covalent, reversible inhibitor of BTK, with a tailored residence time at BTK to reduce off-target effects. In ITP, rilzabrutinib mediates its therapeutic effect through multi-immune modulation by inhibiting B cell activation, interruption of FcgammaR mediated phagocytosis, and potentially amelioration of chronic inflammation associated with ITP.

DrugCentral Search Overview